Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 3/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17723401 | 1.00 | HDAC6 (0.40) | HDAC6MEN1KMT2AFAAHGCGR | |
| SCHEMBL17723360 | 0.86 | ATP1A1 (0.39) | MEN1KMT2AGCGR | |
| SCHEMBL17723385 | 0.86 | ATP1A1 (0.39) | MEN1KMT2AGCGR | |
| SCHEMBL17723366 | 0.78 | HDAC6 (0.40) | HDAC6MEN1KMT2AFAAHPSEN1 | |
| SCHEMBL17723386 | 0.78 | HDAC6 (0.40) | HDAC6MEN1KMT2AFAAHPSEN1 | |
| SCHEMBL17723400 | 0.73 | HDAC6 (0.40) | HDAC6MEN1KMT2AFAAHPSEN1 | |
| SCHEMBL17723860 | 0.71 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL17723410 | 0.71 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL17723310 | 0.70 | SOS1 (0.44) | HDAC6PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL17723326 | 0.70 | SOS1 (0.44) | HDAC6PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117884-B2 | Potent gamma-secretase modulators | THE GENERAL HOSPITAL CORPORATION (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200055840-A1 | POTENT GAMMA-SECRETASE MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-20 | — | — | US | disclosed |
| US-10472346-B2 | Potent gamma-secretase modulators | THE GENERAL HOSPITAL CORPORATION (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180093967-A1 | POTENT GAMMA-SECRETASE MODULATORS | THE GENERAL HOSPITAL CORPORATION | 2018-04-05 | — | — | US | disclosed |
| WO-2016070107-A1 | POTENT GAMMA-SECRETASE MODULATORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055840-A1 | POTENT GAMMA-SECRETASE MODULATORS | BACE1, BACE2, GSAP | HDAC6 792/4885MEN1 4180/4885KMT2A 2542/4885 |
| US-10472346-B2 | Potent gamma-secretase modulators | BACE1, BACE2, APP | HDAC6 1908/4885MEN1 4248/4885KMT2A 3330/4885 |
| US-11117884-B2 | Potent gamma-secretase modulators | BACE1, BACE2, GSAP | HDAC6 792/4885MEN1 4180/4885KMT2A 2542/4885 |
| US-20180093967-A1 | POTENT GAMMA-SECRETASE MODULATORS | BACE1, BACE2, APP | HDAC6 1908/4885MEN1 4248/4885KMT2A 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.